CASE REPORT

Hyperkinetic stereotyped movements in a boy with biallelic CNTNAP2 variants

Marcello Scala¹,²†, Midas Anijs³†, Roberta Battini⁴,⁵, Francesca Madia⁶, Valeria Capra⁶, Paolo Scudieri²,⁶, Alberto Verrotti⁷, Federico Zara⁶, Carlo Minetti¹,², Sonja C. Vernes³,⁸,⁹* and Pasquale Striano¹,²*

Abstract

Background: Heterozygous variants in CNTNAP2 have been implicated in a wide range of neurological phenotypes, including intellectual disability (ID), epilepsy, autistic spectrum disorder (ASD), and impaired language. However, heterozygous variants can also be found in unaffected individuals. Biallelic CNTNAP2 variants are rarer and cause a well-defined genetic syndrome known as CASPR2 deficiency disorder, a condition characterised by ID, early-onset refractory epilepsy, language impairment, and autistic features.

Case-report: A 7-year-old boy presented with hyperkinetic stereotyped movements that started during early infancy and persisted over childhood. Abnormal movements consisted of rhythmic and repetitive shaking of the four limbs, with evident stereotypic features. Additional clinical features included ID, attention deficit-hyperactivity disorder (ADHD), ASD, and speech impairment, consistent with CASPR2 deficiency disorder. Whole-genome array comparative genomic hybridization detected a maternally inherited 0.402 Mb duplication, which involved intron 1, exon 2, and intron 2 of CNTNAP2 (c.97 +?_209-?dup). The affected region in intron 1 contains a binding site for the transcription factor FOXP2, potentially leading to abnormal CNTNAP2 expression regulation. Sanger sequencing of the coding region of CNTNAP2 also identified a paternally-inherited missense variant c.2752C > T, p.(Leu918Phe).

Conclusion: This case expands the molecular and phenotypic spectrum of CASPR2 deficiency disorder, suggesting that Hyperkinetic stereotyped movements may be a rare, yet significant, clinical feature of this complex neurological disorder. Furthermore, the identification of an in-frame, largely non-coding duplication in CNTNAP2 points to a sophisticated underlying molecular mechanism, likely involving impaired FOXP2 binding.

Keywords: CASPR2, Intragenic duplication, Hyperkinetic movement disorder, Hyperkinesia, Speech impairment, Intellectual disability, Autism

Background

Biallelic CNTNAP2 variants cause CASPR2 deficiency disorder (CDD), a syndromic neurodevelopmental disorder involving refractory epilepsy, ID, language impairment, and autistic features [1–4]. Heterozygous variants in CNTNAP2 have also been identified in patients with a wide range of complex neurological phenotypes, but such variants can also be found in unaffected individuals [5, 6].

CASPR2, the protein product of CNTNAP2, is a transmembrane cell adhesion molecule from the neurexin family that is widely expressed throughout the brain [5, 7]. CASPR2 localises to juxtaparanodes of myelinated axons, where it is involved in neuron-glia interactions, and mediates the clustering of potassium channels via interaction with contactin 2 (also known as TAG-1) [8, 9]. CASPR2 is also localised to the synapse where it is...
involved in several additional processes, such as neuronal migration, neurite development and synapse maturation, stability, and function [10–14].

We describe a patient carrying compound heterozygous variants in CNTNAP2 including a missense variant and an intragenic duplication that were inherited from the father and mother, respectively. In addition to the common features found in CASPR2 deficiency disorder (ID, ADHD, ASD, and speech impairment), the boy presented with peculiar hyperkinetic stereotyped movements, expanding the molecular and phenotypic spectrum of CDD.

**Case presentation**

This case was a 7-year-old boy without a family history of neurodevelopmental disability, born to term non-consanguineous healthy parents (Fig. 1A) following a twin pregnancy complicated by intrauterine growth restriction and preeclampsia. His dizygotic twin brother was healthy at birth but was diagnosed with absence epilepsy during infancy. The neonatal course was characterised by feeding difficulties leading to failure to thrive. At 3 months of age, recurrent episodes of crying associated with semi-continuous, repetitive jerky movements of upper and lower limbs were observed, which were diagnosed as hyperkinetic stereotyped movements (Supplementary Video 1).

These paroxysmal hyperkinetic-dyskinetic episodes occurred periodically without any trigger, lasted 10–12 h, and mimicked infantile colics. Their frequency was temporarily reduced when anti-reflux formulas and ranitidine were administered for concomitant recurrent vomiting. Electroencephalogram and brain magnetic resonance imaging were unremarkable.

During his first years of life, the patient displayed ADHD and autistic traits. The boy also featured a phonological processing deficiency and clumsiness in gross and fine movements was also observed. His neuropsychological evaluation (WPPSI-III at age 6 years) revealed a global IQ of 71 (verbal, 86; performance, 68; processing, 55). The movement disorder persisted during the following years through non-triggered fast, high-amplitude, rhythmic, continuous and repetitive shaking involving the four limbs with stereotypic features (Supplementary Videos 2–3). His stereotypic movement disorder had been diagnosed as tics before, which indeed tend to appear from age 6–7 years [15]. However, these repetitive movements already started before the age of 3 and consisted of intense patterns of movement that ran longer than tics and were more bilateral than tics. Several medications, including carbamazepine, valproate, gabapentin, levodopa, flunarizine, benzodiazepines, did not improve his symptoms. The boy is currently receiving clonazepam, 0.2 mg/Kg in two daily doses.

**Genetic findings**

Written informed consent was obtained from the patient’s parents. Whole-genome array-CGH on peripheral blood genomic DNA of the family quartet revealed a maternally inherited CNTNAP2 variant c.97 +?_209-?dup in the proband. Real-time quantitative PCR confirmed that this 0.402 Mbp duplication involved part of intron 1 and exon 2, with a breakpoint within intron 2 (Fig. 1C). This duplication is not predicted to introduce a frameshift in the CASPR2 protein. The duplication was not inherited by the sibling.

PCR amplification and Sanger sequencing was performed to screen CNTNAP2 exons in the family, revealing a paternally inherited missense variant c.2752C>T, p.(Leu918Phe) in the proband (Fig. 1B). This variant is absent from the gnomAD dataset (https://gnomad.broadinstitute.org/variant/) and affects a conserved residue within the Laminin G-like (LG) 3 domain (GERP = 5.49). It is reported In ClinVar (allele ID 924741, https://www.ncbi.nlm.nih.gov/clinvar/variation/949154/) and predicted damaging by in silico tools (e.g., DANN, 0.9977; Mutation Taster, 1; CADD, 24.1). Both variants were absent in the proband’s sibling. Further details are available in Supplementary Methods.

**Discussion**

The range of clinical symptoms found in patients harboring biallelic CNTNAP2 variants are collectively described as CASPR2 deficiency disorder. Dyskinetic features are not included amongst the classic neurological manifestations of this condition [1–4]. In this patient, we observed hyperkinetic stereotyped movements consisting of continuous, repetitive and rhythmic shaking of the four limbs, which became evident during the first months of life and persisted over the years. These abnormal movements did not resemble generalised dystonia, paroxysmal non-kinesigenic dyskinesia, or paroxysmal kinesigenic dyskinesia, but rather represent a novel neurological manifestation of CASPR2 deficiency disorder. This dyskinetic phenotype may be related to the role of CASPR2 in facilitating nerve conduction and synaptic connectivity, particularly given its widespread expression in the central and peripheral nervous system [5, 9, 14]. In patients harboring biallelic variants in CNTNAP2, brain MRI may be normal, such as in our case, or show cortical dysplasia (cortical dysplasia-focal epilepsy syndrome, CDHES).1–3 Additional findings include cerebellar abnormalities (vermian hypoplasia or atrophy) and nonspecific white matter abnormalities.1,2

The c.97 +?_209-?dup and p.(Leu918Phe) variants were inherited from unaffected parents, supporting the incomplete penetrance of heterozygous CNTNAP2 variants [5, 6]. The maternally inherited variant (c.97 +?_209-?dup) involved a complete duplication of exon 2
(99 bp) (Fig. 1D), which may negatively impact protein folding and/or protein-protein interactions. Indeed, exon 2 encodes part of the discoidin homology domain, which is found in the extracellular portion CASPR2 and is known to mediate protein-protein interactions, pointing to a potential perturbation of this mechanism in the patient (Fig. 1E). The paternally inherited missense variant p.(Leu918Phe) is also in the extracellular portion of CASPR2, but is found in the third LG domain (Fig. 1E). Missense variants in the extracellular portion of CASPR2 have been shown to impair interactions with contactin 2 and affect axon growth in cortical neurons [12]. This effect is likely related to the trans-synaptic bridge formed in neurons by the interaction of CASPR2 and contactin 2 that contributes to synaptic organization and synaptic transmission [16]. It would therefore be of value to determine if the variants identified in this patient have functional consequences for protein-protein interactions, or for synaptic or juxtaparanodal organisation and signalling. Such functional studies may shed light on why heterozygous CNTNAP2 variants show incomplete penetrance and why biallelic mutations together produce a range of phenotypes, including the novel motor phenotype described herein.
The maternal duplication also has the potential to alter the regulation of CNTNAP2. The transcription factor FOXP2 targets a binding site in intron 1 of CNTNAP2 and regulates its expression. Mutations in FOXP2 are a monogenic cause of childhood apraxia of speech (SPCH1, OMIM #602081) [17] and CNTNAP2 is functionally implicated in the aetiology of this condition as part of the downstream network of FOXP2 target genes [18]. This is supported by a genetic association of CNTNAP2 variants with phonological memory performance in children with specific language impairment [18]. Duplication of the FOXP2 target site in intron 1 of the maternally inherited allele could alter FOXP2-mediated regulation of CNTNAP2 and lead to aberrant CASPR2 levels, a hypothesis that needs functional testing in cell or animal models. In this way, it is possible that the intronic duplication could contribute to neurodevelopmental or speech phenotypes in patients that are related to both FOXP2 and CNTNAP2, such as phonological processing.

This study has two main limitations. First, a proper functional characterization of the two detected CNTNAP2 variants to evaluate their impact on protein structure and function could not be performed. Second, it was not possible to further investigate the presence of additional variants with a potential modifier effect on the clinical phenotype through Next Generation Sequencing (NGS) techniques, such as whole exome sequencing (WES) or whole genome sequencing (WGS).

Conclusion

This case of a boy with hyperkinetic stereotyped movements and biallelic CNTNAP2 mutations expands our knowledge about CNTNAP2-related disorders. It presents a new, rare neurological manifestation for CDD and posits a remarkable molecular mechanism in which coding and non-coding CNTNAP2 mutations could contribute to the observed phenotypes. Accordingly, we suggest screening CNTNAP2 regulatory regions in patients with a CDD-suggestive phenotype even if a single heterozygous CNTNAP2 variant has been identified or if atypical neurological phenotypes are also present. This will lead to better diagnoses that can improve the management of patients with these disorders. This, together with functional studies of the consequences of the identified mutations, will advance our scientific understanding of disease genes like CNTNAP2.

Abbreviations

ADHD: Attention deficit-hyperactivity disorder; ASD: Autism spectrum disorder; CDD: CASPR2 deficiency disorder; ID: Intellectual disability; NGS: Next Generation Sequencing; WES: Whole exome sequencing; WGS: Whole genome sequencing

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13052-021-01162-w.

**Additional file 1.**

**Additional file 2.**

**Additional file 3.**

**Additional file 4.**

**Acknowledgements**

We thank the patient and his parents for their kind cooperation and the consent to the publication of this study.

**Authors’ contributions**

MS, MA, SCV, and PS conceived and designed the study. MS, RB, FM, VC, and PS clinically reviewed the case and contributed clinical data. MA and SCV designed and carried out molecular studies. MS, MA, SCV, PS, AV, FZ, and CM analysed and interpreted the data. MS and MA drafted the manuscript. SCV and PS supervised the drafting of and edited the manuscript. All authors read, critically revised, and approved the final manuscript.

**Funding**

SCV was supported by a Max Planck Research Group awarded by the Max Planck Gesellschaft, a Human Frontiers Science Program Grant (RGP0058/2016), and a URF Future Leaders Fellowship (MR/T021985/1). MA was supported by an International Max Planck Research School (IMPRS) PhD Fellowship from the Max Planck Institute for Psycholinguistics.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

The patient’s parents provided written informed consent to exome sequencing and inclusion into the research study approved by the Giannina Gaslini Children’s Institute Ethics Committee.

**Consent for publication**

A signed consent for this publication has been obtained from the patient and his parents.

**Competing interests**

All authors declare no disclosures relevant to the manuscript.

**Author details**

1Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. 2Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health University of Genoa, Genoa, Italy. 3Neurogenetics of Vocal Communication Group, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands. 4Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 5IRCCS Fondazione Stella Maris, Pisa, Italy. 6Medical Genetic Unit, IRCCS Istituto G. Gaslini, Genoa, Italy. 7Department of Pediatrics, University of Perugia, Perugia, Italy. 8School of Biology, University of St Andrews, Fife, UK. 9Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.

Received: 7 July 2021 Accepted: 25 September 2021
Published online: 12 October 2021

**References**

1. Rodenas-Cuadrado P, Pietrafusa N, Francavilla T, La Neve A, Straiano P, Vernes SC. Characterisation of CASPR2 deficiency disorder—a syndrome involving autism, epilepsy and language impairment. BMC Med Genet. 2016;17(1):8. https://doi.org/10.1186/s12881-016-0272-8.

2. Smogovac M, Cleall A, Hoyer J, Lederer D, Nassogne MC, Palmer EE, et al. Eight further individuals with intellectual disability and epilepsy carrying biallelic CNTNAP2 aberrations allow delineation of the mutational and
phenotypic spectrum. J Med Genet. 2016;53(12):820–7. https://doi.org/10.1136/jmedgenet-2016-103880.

3. Zweter C, de Jong EK, Zweter M, Orrico A, Ousager LB, Collins AL, et al. CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila. Am J Hum Genet. 2009;85(5):655–66. https://doi.org/10.1016/j.ajhg.2009.10.004.

4. Watson CM, Crinnion LA, Tzika A, Mills A, Coates A, Pendlebury M, et al. Diagnostic whole genome sequencing and split-read mapping for nucleotide resolution breakpoint identification in CNTNAP2 deficiency syndrome. Am J Med Genet A. 2014;164a(10):2649–55.

5. Rodenas-Cuadrado P, Ho J, Vennes SC. Shining a light on CNTNAP2: complex functions to complex disorders. Eur J Hum Genet. 2014;22(2):171–8. https://doi.org/10.1038/ejhg.2013.100.

6. Tomà C, Pierce KD, Shaw AD, Heath A, Mitchell PB, Schofield PR, et al. Comprehensive cross-disorder analyses of CNTNAP2 suggest it is unlikely to be a primary risk gene for psychiatric disorders. PLoS Genet. 2018;14(12): e1007535. https://doi.org/10.1371/journal.pgen.1007535.

7. Gordon A, Salomon D, Barak N, Pen Y, Tsoory M, Kimchi T, et al. Expression of Cntnap2 (Caspr2) in multiple levels of sensory systems. Mol Cell Neurosci. 2016;70:42–53. https://doi.org/10.1016/j.mcn.2015.11.012.

8. Poliak S, Gollan L, Salomon D, Berglund EO, Oghara R, Ranscht B, et al. Localization of Caspr2 in myelinated nerves depends on axon-glia interactions and the generation of barriers along the axon. J Neurosci. 2001;21(19):7568–75. https://doi.org/10.1523/JNEUROSCI.21-19-07568.2001.

9. Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B, Pevny L, et al. Juxtaparanodal clustering of shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol. 2003;162(6):1149–60. https://doi.org/10.1083/jcb.200305018.

10. Perlarganeko O, Abrahms BS, Herman B, Winden KD, Gdalyahu A, Dong H, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011;147(1):235–46. https://doi.org/10.1016/j.cell.2011.08.040.

11. Anderson GR, Galfin T, Xu W, Aoto J, Malenka RC, Südhof TC. Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc Natl Acad Sci U S A. 2012;109(46):18120–5. https://doi.org/10.1073/pnas.1216398109.

12. Goullancourt A, Canali G, Girault J-A, Ogulevetskaya K, Garcia M, Goutebroze L, et al. Genetic variants in autism-related CNTNAP2 impair axonal growth of cortical neurons. Hum Mol Genet. 2018;27(11):1941–54. https://doi.org/10.1093/hmg/ddy102.

13. Varea O, Martin-de-Saavedra MD, Kopeikina KJ, Schürmann B, Fleming HJ, Fawcett-Patel JM, et al. Synaptic abnormalities and cytoplasmic glutamate receptor aggregates in contactin-associated protein-like 2/Caspr2 knockout neurons. Proc Natl Acad Sci U S A. 2015;112(19):6176–81. https://doi.org/10.1073/pnas.1423205112.

14. Lazarro MT, Taxidis J, Shuman T, Bachmutsy I, Ikrar T, Santos R, et al. Reduced Prefrontal Synaptic Connectivity and Disturbed Oscillatory Population Dynamics in the CNTNAP2 Model of Autism. Cell Rep. 2019;27(9):2567–78.e6.

15. Zinner SH, Mink JW. Movement disorders I: tics and stereotypes. Pediatr Rev. 2010;31(6):223–33. https://doi.org/10.1542/pir.31-6-223.

16. Lu Z, Reddy MV, Liu J, Kalichava A, Liu J, Zhang L, et al. Molecular architecture of Contactin-associated protein-like 2 (CNTNAP2) and its interaction with Contactin 2 (CNTN2). J Biol Chem. 2016;291(46):24133–47. https://doi.org/10.1074/jbc.M116.748336.

17. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature. 2001;413(6855):519–23. https://doi.org/10.1038/35079076.

18. Vennes SC, Newbury D, Abrahams BS, Winchester L, Nicod J, Groszer M, et al. A functional genetic link between distinct developmental language disorders. N Engl J Med. 2008;359(22):2337–45. https://doi.org/10.1056/NEJMoa0802988.